Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Patrick M. Reagan, David B. Miklos et al.|Journal of Clinical Oncology|2022Cited by 331
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell LymphomaMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Blood|2020Cited by 14
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).Michael Wang, Patrick M. Reagan, Javier Muñoz et al.|Journal of Clinical Oncology|2021Cited by 10
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients (Pts) with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)Michael Wang, Patrick M. Reagan, Javier Muñoz et al.|Transplantation and Cellular Therapy|2021Cited by 2
Abstract 867: Multi-omic characterization of tumor microenvironment evolution in LBCL across treatment lines: Insights from Atlas classification and axicabtagene ciloleucel trialsMichael Mattie, Jérôme Galon, Régis Perbost et al.|Cancer Research|2025Cited by 0